Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET

CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. GNCA, a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 4, 2017 at 9:00 a.m. ET to discuss financial results for the first quarter 2017. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 13446635. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.

About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and to identify T cell response signatures of cancer patients treated with checkpoint blockade therapies to potentially improve clinical practice. Genocea expects GEN-003 to be ready to begin Phase 3 development and to file an IND for its neoantigen cancer vaccine candidate GEN-009 by the end of 2017. For more information, please visit the company's website at www.genocea.com.

For media: 
Jennifer LaVin 
O: 617-715-6687
jennifer.lavin@genocea.com 

For investors: 
Jonathan Poole
O: 617-876-8191 
jonathan.poole@genocea.com